mFOLFOX7

DRUG2 trials

Sponsors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Washington University School of Medicine

Conditions

Colorectal CancerEsophageal CancerEsophagus CancerGastric CancerGastroesophageal Junction CancerStomach Cancer

Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

RecruitingNCT05187182

Washington University School of MedicineEsophageal Cancer, Esophagus Cancer, Gastric Cancer +2

Start: 2023-06-02End: 2028-06-30Target: 42Updated: 2026-03-18

Phase 2

Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

CompletedNCT03530267

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestColorectal Cancer

Start: 2018-09-28End: 2024-02-01Updated: 2024-02-23

Related Papers

Phase I trial of emavusertib (CA-4948) in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated, unresectable gastric and esophageal cancer.

Journal of Clinical Oncology2026-01-10

Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.

Journal of Clinical Oncology2022-06-013 citations